Sökning: id:"swepub:oai:lup.lub.lu.se:b28cbe74-33ca-4ab5-9891-09e6bb4ba438" >
Effects of TCF7L2 r...
Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes
-
- Dujic, Tanja (författare)
- University of Sarajevo
-
- Bego, Tamer (författare)
- University of Sarajevo
-
- Malenica, Maja (författare)
- University of Sarajevo
-
visa fler...
-
- Velija-Asimi, Zelija (författare)
- University of Sarajevo
-
- Ahlqvist, Emma (författare)
- Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups
-
- Groop, Leif (författare)
- Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups
-
- Pearson, Ewan R. (författare)
- University of Dundee
-
- Causevic, Adlija (författare)
- University of Sarajevo
-
- Semiz, Sabina (författare)
- University of Sarajevo
-
visa färre...
-
(creator_code:org_t)
- 2019-05-09
- 2019
- Engelska.
-
Ingår i: Bosnian Journal of Basic Medical Sciences. - : Association of Basic Medical Sciences of FBIH. - 1512-8601 .- 1840-4812. ; 19:4, s. 368-374
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
http://www.bjbms.org...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The response to metformin, the most commonly used drug for the treatment of type 2 diabetes (T2D), is highly variable. The common variant rs7903146 C>T within the transcription factor 7-like 2 gene (TCF7L2) is the strongest genetic risk factor associated with T2D to date. In this study, we explored the effects of the TCF7L2 rs7903146 genotype on metformin response in T2D. The study included 86 newly diagnosed patients with T2D, incident users of metformin. Levels of fasting glucose, insulin, HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and anthropometric parameters were measured prior to metformin therapy, and 6 and 12 months after the treatment. Genotyping of the TCF7L2 rs7903146 was performed by the Sequenom MassARRAY® iPLEX® platform. At baseline, the diabetes risk allele (T) showed an association with lower triglyceride levels (p = 0.037). After 12 months of metformin treatment, the T allele was associated with 25.9% lower fasting insulin levels (95% CI 10.9-38.3%, p = 0.002) and 29.1% lower HOMA-IR index (95% CI 10.1-44.1%, p = 0.005), after adjustment for baseline values. Moreover, the T allele was associated with 6.7% lower fasting glucose levels (95% CI 1.1-12.0%, p = 0.021), adjusted for baseline glucose and baseline HOMA-%B levels, after 6 months of metformin treatment. This effect was more pronounced in the TT carriers who had 16.8% lower fasting glucose levels (95% CI 7.0-25.6%, p = 0.002) compared to the patients with CC genotype. Our results suggest that the TCF7L2 rs7903146 variant affects markers of insulin resistance and glycemic response to metformin in newly diagnosed patients with T2D within the first year of metformin treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Metformin
- Pharmacogenetics
- TCF7L2
- Transcription factor 7-like 2 gene
- Type 2 diabetes
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas